Triple
T33637330
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | RE-LY trial |
E861731
|
entity |
| Predicate | anticoagulantMechanismStudied |
P149318
|
FINISHED |
| Object | direct thrombin inhibition |
—
|
LITERAL FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: direct thrombin inhibition | Statement: [RE-LY trial, anticoagulantMechanismStudied, direct thrombin inhibition]
PD
Predicate disambiguation
gpt-5-mini-2025-08-07
Target predicate: anticoagulantMechanismStudied Context triple: [RE-LY trial, anticoagulantMechanismStudied, direct thrombin inhibition]
-
A.
mechanismOfActionStudied
chosen
Indicates that the relationship involves examining or investigating how an action, intervention, or agent produces its effects or outcomes.
-
B.
coagulationAgent
Indicates that one entity serves as or contains a substance that promotes or causes the coagulation (clotting or thickening) of another entity.
-
C.
coagulationTime
Indicates the duration required for a substance, typically a liquid like blood or a solution, to undergo coagulation and form a solid or semi-solid clot.
-
D.
coagulationType
Indicates the specific kind or category of coagulation process or method associated with an entity.
-
E.
hasDrugInteractionMechanism
Indicates that one substance affects another through a specific biological, chemical, or pharmacological mechanism that alters its drug action or effects.
- F. None of above.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69f3498280c48190bcc3494017d14234 |
completed | April 30, 2026, 12:22 p.m. |
| NER | Named-entity recognition | batch_69f6fb19063c81909466b329655c8583 |
completed | May 3, 2026, 7:36 a.m. |
| PD | Predicate disambiguation | batch_69f6f96badb08190994442c2aba840b1 |
completed | May 3, 2026, 7:29 a.m. |
Created at: May 1, 2026, 1:42 a.m.